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Rationale: There is limited evidence supporting the routine use of palivizumab in paediatric cystic fibrosis (CF)
patients to reduce respiratory syncytial virus (RSV) infection and related hospitalisation. Despite this, anti-RSV
prophylaxis is increasingly common. This is the first report from Ireland regarding palivizumab outcomes for
children with CF, under 2 years old, despite the greatest prevalence of CF globally.
Methods: An audit was performed at a tertiary hospital in Ireland’s mid-West to document all children with
CF, <24 months old, who received palivizumab over a five year period and comparision made with all eligible children
for the prior five year period who had not received the product (also CF patients). Palivizumab was administered to
both cohorts in their first year of life. Hospitalisation rates were compared using Fisher’s exact test. Incidence of RSV
and Pseudomonas aeruginosa infection was recorded.
Results: A total of 19 patients who received palivizumab were included in the study; comparision was made with a
retrospective control group of 30 patients. Prophylactic palivizumab did not prevent hospitalisation for 10/19 patients, 3
of whom were affected by RSV. This was significantly greater than in the control group, where no hospitalisations were
recorded (p < 0.0001). P. aeruginosa was isolated in one case from the study cohort, while no P. aeruginosa was detected
in the control group.
Conclusions: This study, the first of its kind from Ireland where CF prevalence is highest, does not provide unequivocal
support for prophylactic use of palivizumab in CF patients under 2 years. Despite being derived from a small sample size,
based on these data and complementary clinical observation, we have discontinued such prophylaxis. However, should
reported incidence of RSV-related hospitalisation increase, there is scientific plausibility for appropriately powered,
randomised, controlled trials of palivizumab.
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Dear Editor,
Respiratory syncytial virus (RSV) is the most commonly
attributed cause of lower respiratory tract infections in
young infants [1]. As RSV is recognised as affecting almost
100 % of children by 24 months, the use of anti-RSV
prophylaxis, in the form of humanised monoclonal anti-
body palivizumab, has become ubiquitous due to its safety
and efficacy profile, especially in the context of preventing
hospitalisation of high-risk children, such as those born
pre-maturely [1, 2]. Globally, Ireland has the highest preva-
lence of cystic fibrosis (CF) (2.98 per 10,000 population)* Correspondence: colum.dunne@ul.ie
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both bacterial and viral respiratory infection. Despite this,
there is no previous report of palivizumab’s prophylactic ef-
ficacy in a cohort of Irish CF patient under 24 months.
In the context of paediatric patients, such as those
with CF at risk of RSV-related hospitalization, there has
been considerable expert discussion regarding effective-
ness of palivizumab use, which can be summarized as
consensus that insufficient data exist to concretely sup-
port the economics, safety and tolerability of its use in
this setting [4–6]. Of the extant studies, respondents to
a United Kingdom-based survey would prescribe palivi-
zumab if funding were not an issue [7] and, although a
large number of CF physicians in North America have
prescribed palivizumab to CF infants in their first year ofe is distributed under the terms of the Creative Commons Attribution 4.0
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has been identified as a main cause of hospitalisation in
cystic fibrosis (CF) infants, however, hospitalisation was
most commonly associated with concomitant bacterial
infection and the most severe symptoms of lower airway
inflammation were seen in those patients co-infected with
RSV and Pseudomonas aeruginosa [9]. Indeed, RSV has
been proven to enhance P. aeruginosa infection of respira-
tory epithelial cells, suggesting a role for viral-bacterial
interactions in exacerbations of CF lung disease [10]. To
the best of our knowledge, only one study has reported
the effects of palivizumab on P. aeruginosa colonization,
with a lack of demonstrable efficacy over placebo [11].
Here, with ethical approval, we performed an audit at
University Hospital Limerick (Ireland), a tertiary referral
centre, to document all children with CF, <24 months old,
who received palivizumab during their first year of life
(once a month for up to 7 months), over a 5-year period.
We compared the data with those of all eligible children
with cystic fibrosis for the prior 5 year period who had not
received the product. In both cohorts, assessment in-
cluded: respiratory related hospitalisation; differential
diagnosis; nasopharyngeal aspirate; and (due to the as-
sociation between palivizumab and subsequent Pseudo-
monas infection) colonisation of the lower airways by
P. aeruginosa at initiation of palivizumab prophylaxis
or in the subsequent 12 months. Data are presented as
mean ± standard error. Fisher’s exact test was used to
compare hospitalisation rates of both groups.
In summary, 19 patients received palivizumab (mean
doses: 5.2 ± 0.37) and met the criteria for inclusion in
the study group, while 30 CF infants who attended UHL
from 2004 to 2009, did not receive palivizumab and con-
stituted the control group. Ten patients (53 %) who re-
ceived prophylactic palivizumab were hospitalised (mean
age at admission: 3.1 ± 0.98 months), with 3 of those
cases confirmed using molecular techniques as relating
to RSV. Mean age at time of first palivizumab treatment
was 5.5 ± 0.74 months. P. aeruginosa was isolated from
one of those children the following year. No children
from the control group were hospitalised (p < 0.0001),
and no P. aeruginosa detected.
These results complement previous reports of prophy-
lactic anti-RSV strategies for children, but add consider-
ably to existing knowledge in detailing outcomes from a
geographic region in which prophylaxis could have been
especially valuable for paediatric CF patients had a bene-
fit been evident. We observed a low rate of RSV-related
hospitalisations overall, in addition to a small sample size,
similar to elsewhere, that impaired ability to draw statisti-
cally relevant conclusions. However, due to economic con-
straints and the lack of supportive clinical evidence,
palivizumab prophylaxis was discontinued. Our study
was limited by not assessing the impact of palivizumabintervention in RSV season only and, furthermore, our
results do not address other aspects of palivizumab use
or potential benefit, including: its role in infants diag-
nosed with CF by newborn screening; the possibility that
changes to timing of palivizumab administration (when to
begin and duration of spacing) may improve performance;
similarly, whether increased dosage could enhance out-
comes; use therapeutically; emergence of resistance; or
variation of antigenic presentation affecting efficacy. How-
ever, previous reports on the use of palivizumab in RSV-
hospitalisations have demonstrated positive effects [12–14].
Therefore, in summary, we believe that, should reported in-
cidence of RSV-related hospitalisation increase, there is sci-
entific plausibility for appropriately powered, randomised,
controlled trials of palivizumab.
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